New clinical trial design in precision medicine: discovery, development and direction

Assessing Medpace Hldgs: Insights From 9 Financial Analysts

In the latest quarter, 9 analysts provided ratings for Medpace Hldgs MEDP, showcasing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 1 0 0 2M Ago 0 0 1 0 0 3M Ago 2 2 1 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $402.67, a high estimate of $469.00, and a low estimate of $336.00. A decline of 7.99% from the prior average price target is evident in the current average.

Exploring Analyst Ratings: An In-Depth Overview

A clear picture of Medpace Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Dan Leonard UBS Lowers Neutral $350.00 $420.00 David Windley Jefferies Lowers Hold $345.00 $415.00 Eric Coldwell Baird Lowers Outperform $413.00 $430.00 Jailendra Singh Truist Securities Announces Hold $415.00 - Sandy Draper Guggenheim Lowers Buy $432.00 $464.00 Eric Coldwell Baird Lowers Outperform $430.00 $469.00 Justin Bowers Deutsche Bank Lowers Hold $336.00 $395.00 Charles Rhyee TD Cowen Lowers Buy $434.00 $452.00 Eric Coldwell Baird Raises Outperform $469.00 $456.00 Key Insights:

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Medpace Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.

Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medpace Hldgs compared to the broader market.

Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Medpace Hldgs's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into Medpace Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Medpace Hldgs analyst ratings.

All You Need to Know About Medpace Hldgs

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Medpace Hldgs: Delving into Financials

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Positive Revenue Trend: Examining Medpace Hldgs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.59% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Medpace Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.73% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Medpace Hldgs's ROE excels beyond industry benchmarks, reaching 12.31%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Medpace Hldgs's ROA excels beyond industry benchmarks, reaching 4.76%. This signifies efficient management of assets and strong financial health.

Debt Management: Medpace Hldgs's debt-to-equity ratio is below the industry average at 0.17, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.Com. Benzinga does not provide investment advice. All rights reserved.

Maintaining Hold On Medpace Holdings Amid Market Headwinds And Revised Growth Expectations

Medpace Holdings (MEDP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Dan Leonard from UBS maintained a Hold rating on the stock and has a $350.00 price target.

Dan Leonard has given his Hold rating due to a combination of factors involving the current and anticipated challenges that Medpace Holdings is facing. The crux of the concern stems from a decrease in biotech funding, a decline in year-to-date bookings, sluggish hiring practices, and an uncertain pace of biopharmaceutical mergers and acquisitions. These elements collectively suggest that Medpace might struggle to sustain the double-digit sales growth by 2025, which was previously anticipated. Although Leonard acknowledges Medpace's potential to grow faster than its peers in the clinical research organization sector over the long term, the immediate impact of these headwinds is believed to be underestimated in the market.Furthermore, Medpace's conservative approach to its backlog policy, which could lead to a lower reporting of future bookings due to cancellations, is a factor in the Hold rating. This conservative methodology, coupled with a hiring slowdown evidenced by flat headcount growth over the past year, tempers expectations for near-term growth. This is particularly significant in light of the company's historical growth rates. Leonard's analysis leads to a reduction in Medpace's price target, from $420 to $350, reflecting a more modest premium over peers in light of the revised growth outlook and potential for downward earnings revisions. Despite the reduced price target, a premium valuation is still justified by the relatively higher market growth rate for small and mid-size biotech research and development.

In another report released on September 25, Jefferies also downgraded the stock to a Hold with a $345.00 price target.

MEDP's price has also changed moderately for the past six months – from $402.750 to $326.260, which is a -18.99% drop .

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Medpace Holdings (MEDP) Company Description:

Medpace Holdings, Inc. Engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.

Medpace Holdings, Inc.

Medpace Holdings, Inc. Engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

read more

---